Clinical trial
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
NCT04051606 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
- Lead sponsor
- Case Comprehensive Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2019
- Completion date
- March 20, 2024
- Enrollment
- 14 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent glioblastoma